Hui Zhao1, Ning Zhang1, Vivian Ho2, Minming Ding3, Weiguo He1, Jiangong Niu1, Ming Yang1, Xianglin L Du4, Daria Zorzi1, Mariana Chavez-MacGregor1,5, Sharon H Giordano1,5. 1. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Economics, Rice University, Houston, Texas. 3. Division of Biostatistics, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. 4. Division of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. 5. Breast Medical Oncology Department, The University of Texas Health Science Center at Houston, Houston, Texas.
Abstract
BACKGROUND: Treatment guidelines for colon cancer recommend colectomy with lymphadenectomy of at least 12 lymph nodes for patients with stage I to stage III disease as surgery adherence (SA) and adjuvant chemotherapy for individuals with stage III disease. Herein, the authors evaluated adherence to these guidelines among older patients in Texas with colon cancer and the associated survival outcomes. METHODS: Using Texas Cancer Registry data linked with Medicare data, the authors included patients with AJCC stage II and III colon cancer who were aged ≥66 years and diagnosed between 2001 and 2011. SA and adjuvant chemotherapy adherence rates to treatment guidelines were estimated. The chi-square test, general linear regression, survival probability, and Cox regression were used to identify factors associated with adherence and survival. RESULTS: The rate of SA increased from 47.2% to 84% among 6029 patients with stage II or stage III disease from 2001 to 2011, and the rate of adjuvant chemotherapy increased from 48.9% to 53.1% for patients with stage III disease during the same time period. SA was associated with marital status, tumor size, surgeon specialty, and year of diagnosis. Patient age, sex, marital status, Medicare state buy-in status, comorbidity status, and year of diagnosis were found to be associated with adjuvant chemotherapy. The 5-year survival probability for patients receiving guideline-concordant treatment was the highest at 87% for patients with stage II disease and was 73% for those with stage III disease. After adjusting for demographic and tumor characteristics, improved cancer cause-specific survival was associated with the receipt of stage-specific, guideline-concordant treatment for patients with stage II or stage III disease. CONCLUSIONS: The adherence to guideline-concordant treatment among older patients with colon cancer residing in Texas improved over time, and was associated with better survival outcomes. Future studies should be focused on identifying interventions to improve guideline-concordant treatment adherence. Cancer 2018;124:679-87.
BACKGROUND: Treatment guidelines for colon cancer recommend colectomy with lymphadenectomy of at least 12 lymph nodes for patients with stage I to stage III disease as surgery adherence (SA) and adjuvant chemotherapy for individuals with stage III disease. Herein, the authors evaluated adherence to these guidelines among older patients in Texas with colon cancer and the associated survival outcomes. METHODS: Using Texas Cancer Registry data linked with Medicare data, the authors included patients with AJCC stage II and III colon cancer who were aged ≥66 years and diagnosed between 2001 and 2011. SA and adjuvant chemotherapy adherence rates to treatment guidelines were estimated. The chi-square test, general linear regression, survival probability, and Cox regression were used to identify factors associated with adherence and survival. RESULTS: The rate of SA increased from 47.2% to 84% among 6029 patients with stage II or stage III disease from 2001 to 2011, and the rate of adjuvant chemotherapy increased from 48.9% to 53.1% for patients with stage III disease during the same time period. SA was associated with marital status, tumor size, surgeon specialty, and year of diagnosis. Patient age, sex, marital status, Medicare state buy-in status, comorbidity status, and year of diagnosis were found to be associated with adjuvant chemotherapy. The 5-year survival probability for patients receiving guideline-concordant treatment was the highest at 87% for patients with stage II disease and was 73% for those with stage III disease. After adjusting for demographic and tumor characteristics, improved cancer cause-specific survival was associated with the receipt of stage-specific, guideline-concordant treatment for patients with stage II or stage III disease. CONCLUSIONS: The adherence to guideline-concordant treatment among older patients with colon cancer residing in Texas improved over time, and was associated with better survival outcomes. Future studies should be focused on identifying interventions to improve guideline-concordant treatment adherence. Cancer 2018;124:679-87.
Authors: Hanna K Sanoff; William R Carpenter; Til Stürmer; Richard M Goldberg; Christopher F Martin; Jason P Fine; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Joyce Niland; Katherine L Kahn; Maria J Schymura; Deborah Schrag Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Joan L Warren; Eboneé N Butler; Jennifer Stevens; Christopher S Lathan; Anne-Michelle Noone; Kevin C Ward; Linda C Harlan Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: Daniel G Haller; Paul J Catalano; John S Macdonald; Mark A O'Rourke; Michael S Frontiera; Don V Jackson; Robert J Mayer Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: Ryaz Chagpar; Yan Xing; Yi-Ju Chiang; Barry W Feig; George J Chang; Y Nancy You; Janice N Cormier Journal: J Clin Oncol Date: 2012-02-21 Impact factor: 44.544
Authors: Genevieve M Boland; George J Chang; Alex B Haynes; Yi-Ju Chiang; Ryaz Chagpar; Yan Xing; Chung-Yuan Hu; Barry W Feig; Y Nancy You; Janice N Cormier Journal: Cancer Date: 2012-12-21 Impact factor: 6.860
Authors: Vivian Ho; Meei-Hsiang Ku-Goto; Hui Zhao; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano Journal: BMC Health Serv Res Date: 2016-07-15 Impact factor: 2.655
Authors: Fa Chen; Fei Wang; Christina E Bailey; Harvey J Murff; Jordan D Berlin; Xiao-Ou Shu; Wei Zheng Journal: Am J Cancer Res Date: 2020-10-01 Impact factor: 6.166
Authors: Amy R MacKenzie; Andrea M Barsevick; Ronald Myers; Sarah E Hegarty; Scott W Keith; Sheel Patel; Evan Lapinsky; Joshua Schoppe; Ulysses Williams; Andrew E Chapman Journal: J Geriatr Oncol Date: 2019-03-06 Impact factor: 3.929
Authors: Leila T Tchelebi; Biyi Shen; Ming Wang; Louis Potters; Joseph Herman; Daniel Boffa; Joel E Segel; Henry S Park; Nicholas G Zaorsky Journal: Adv Radiat Oncol Date: 2022-03-08
Authors: Zeta Chow; Tong Gan; Quan Chen; Bin Huang; Nancy Schoenberg; Mark Dignan; B Mark Evers; Avinash S Bhakta Journal: J Am Coll Surg Date: 2020-02-13 Impact factor: 6.532
Authors: E Aranda; E Polo; C Camps; A Carrato; E Díaz-Rubio; V Guillem; R López; A Antón Journal: Clin Transl Oncol Date: 2020-01-23 Impact factor: 3.405